Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

NCT01466972 is registered in ClinicalTrials.gov with Hope Rugo, MD as lead sponsor.

NCT NCT01466972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
Lead sponsor
Hope Rugo, MD
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2012
Completion date
October 2, 2019
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasm